白癜风与斑秃患者及其同胞的黑色素瘤和角质形成细胞癌风险
BACKGROUND: Vitiligo and autoimmune alopecia (AA) are caused by T cell-mediated autoimmunity in genetically predisposed individuals. Studies in vitiligo have reported reduced risks for malignant melanoma (MM), as well as for keratinocyte cancer (KC).…
要点
- 白癜风和斑秃患者的黑色素瘤风险均约为一般人群的一半。
- 斑秃患者鳞状细胞癌风险降低,白癜风患者无显著降低。
- 患者同胞的皮肤癌风险无显著改变,非皮肤癌风险未降低。
核心结论
- 白癜风和斑秃中皮肤癌风险降低超出自身免疫反应靶向的细胞类型。
- 同胞皮肤癌风险轻度降低提示非疾病表型因素的作用。
- 白癜风和斑秃表型或其免疫相关遗传易感性未提供对非皮肤恶性肿瘤的固有保护。
研究设计与样本
- 基于瑞典登记数据链路的 population-based matched cohort study。
- 2006年至2021年纳入15 030例白癜风患者和18 541例斑秃患者,以及各自17 853例和21 821例同胞。
- 使用Cox比例风险回归计算风险比(HR),对比患者与一般人群、患者同胞与一般人群同胞。
主要发现
- 白癜风患者黑色素瘤HR为0.53(95%CI 0.32-0.86),基于17例事件(粗发病率每10万人年=16)。
- 斑秃患者黑色素瘤HR为0.53(95%CI 0.34-0.83),基于20例事件(粗发病率每10万人年=15)。
- 白癜风患者鳞状细胞癌HR为0.81(95%CI 0.53-1.24),基于23例事件(粗发病率每10万人年=22)。
- 斑秃患者鳞状细胞癌HR为0.65(95%CI 0.43-0.98),基于24例事件(粗发病率每10万人年=18)。
- 同胞中黑色素瘤和鳞状细胞癌的HR无统计学显著改变(0.82≤HR≤1.10;P>0.05)。
关键数值与推荐
- 白癜风患者黑色素瘤HR 0.53(95%CI 0.32-0.86)。
- 斑秃患者黑色素瘤HR 0.53(95%CI 0.34-0.83)。
- 斑秃患者鳞状细胞癌HR 0.65(95%CI 0.43-0.98)。
- 同胞中黑色素瘤和鳞状细胞癌HR 0.82-1.10(P>0.05)。
临床怎么用
- 可向白癜风和斑秃患者说明其黑色素瘤风险较一般人群降低。
- 尽管风险降低,仍建议患者及同胞做好防晒。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vitiligo and autoimmune alopecia (AA) are caused by T cell-mediated autoimmunity in genetically predisposed individuals. Studies in vitiligo have reported reduced risks for malignant melanoma (MM), as well as for keratinocyte cancer (KC). Similarly, in AA, reduced risks for KC and MM have been reported. The driving mechanisms (genetic predisposition, immunological or other effects of the disease phenotypes, or environmental factors) remain unclear. Whether or not the immune-related genetic predisposition in vitiligo and AA offers 'inherent' protection against other types of cancer remains unresolved. OBJECTIVES: To investigate the incidence and outcome of MM, squamous cell carcinoma (SCC) and noncutaneous cancers in vitiligo and AA, compared with the general population, and to investigate the corresponding risks in their respective siblings. METHODS: We performed a population-based matched cohort study using data from linkage of Swedish registers. We used Cox proportional hazards regression to calculate hazard ratios (HRs) contrasting patients with vitiligo or AA with the general population, as well as contrasting patients' siblings with siblings of individuals from the general population. RESULTS: Between 2006 and 2021, we included 15 030 patients with vitiligo and 18 541 with AA, along with, respectively, 17 853 and 21 821 of their siblings. Based on 17 MM events [crude incidence rate per 100 000 person-years (IR) = 16] and 23 SCC events (IR = 22) in vitiligo, along with 20 MM events (IR = 15) and 24 SCC events (IR = 18) in AA, the hazard ratio (HR) for MM was 0.53 [95% confidence interval (CI) 0.32-0.86] in vitiligo and 0.53 (95% CI 0.34-0.83) in AA. Regarding SCC, the HR was 0.81 (95% CI 0.53-1.24) in vitiligo and 0.65 (95% CI 0.43-0.98) in AA. Stage at diagnosis of MM did not differ substantially between patients and the general population. Among siblings, HRs for MM and SCC were not statistically significantly altered (0.82 ≤ HR ≤ 1.10; P > 0.05). In patients and their siblings, HRs for noncutaneous solid or haematological cancers were not reduced. CONCLUSIONS: In vitiligo and in AA the decreased risk of cutaneous cancers extends beyond the cell type targeted by the autoimmune reaction. The general tendency towards somewhat reduced skin cancer risks among patients' siblings suggests a role for factors other than the disease phenotypes per se. Neither the vitiligo and AA phenotypes nor their immune-related genetic predispositions seem to offer any 'inherent' protection against noncutaneous malignancies. Vitiligo and alopecia are skin conditions affecting around 2% of the population. Both are autoimmune disorders, where the immune system attacks the person’s own cells. In vitiligo, the immune system attacks skin cells producing the pigment melanin. This causes white patches on the skin. In alopecia, the immune system attacks hair follicles (sacs where hairs develop). This causes hair loss. Both conditions involve similar autoimmune mechanisms and genetic background. Melanin and hair protect against the sun (the main cause of skin cancers), so there could be an increased risk of skin cancers on hairless and white skin, but some studies have found patients have reduced skin cancer risks. We aimed to compare the skin cancer risk in people with vitiligo or alopecia against the risk in people without those conditions. We also looked to see if the effects on skin cancer risks of having these skin conditions are due to genetics. We also wanted to understand whether genetic factors affect overall cancer risks. We studied 15,000 patients with vitiligo, 18,000 with alopecia, and their siblings. Also, we used Swedish national registers to get information about the general population. We found that for patients, compared with the general population, the risk of malignant melanoma (a type of skin cancer) was 50% lower. The risks for other skin cancers were also reduced. In siblings, we found slightly lower risks of malignant melanoma and other skin cancers. There were no changes in risks of other cancer types. Our results could help in advising patients about risks of skin cancers. The results might also give clues to what might cause lower risks of skin cancers in people with vitiligo and alopecia. But even if the risks are reduced, patients and siblings should still protect themselves from the sun.
引用
- Delcoigne B, Lysell J, Askling J, et al. Incidence, stage and outcome of malignant melanoma, keratinocyte and other cancers in individuals with vitiligo or alopecia: intraindividual or familial risks? Br J Dermatol. 2025. PMID: 39999038. doi:10.1093/bjd/ljaf074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。